Advanced Protein Technologies and Drug Development

Bridging the gap of technological advances in life sciences between China and the world

Recombined human IL-33

Catalog Number

LT0138

Synonyms

NF-HEV

Description:

Interleukin-33 (IL-33) was initially discovered as a nuclear factor NF-HEV abundantly expressed in high endothelial venules. It is a 30-32 kD pro-inflammatory protein with intracellular and extracellular activities and a chromatin-associated cytokine of the IL-1 family with high sequence and structural similarity to IL-1 and IL-18. IL-33 is highly and selectively expressed by high endothelial venule endothelial cells (HEVECs) in human tonsils, Peyers's patches, and lymph nodes. It contains a bipartite nuclear localization signal at the C-terminus, and is targeted to the nucleus when ectopically expressed in human umbilical vein endothelial cells (HUVECs) and HeLa cells. The C-terminal fragment, corresponding to mature IL-33, binds and triggers signaling. IL-33 mediates its biological effects via Toll-interleukin 1 (IL-1) receptor (TIR) domain-containing receptor ST2, activates NF-kappaB and MAP kinases, and drives production of T(H)2-associated cytokines from in vitro polarized T(H)2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs. Human IL-33 is 270 amino acids in length.

Sequence

SITGISPITE YLASLSTYND QSITFALEDE SYEIYVEDLK KDEKKDKVLL SYYESQHPSN ESGDGVDGKM LMVTLSPTKD FWLHANNKEH SVELHKCEKP LPDQAFFVLH NMHSNCVSFE CKTDPGVFIG VKDNHLALIK VDSSENLCTE NILFKLSET

Source:

E.coli

Purity:

Greater than 98% by SDS-PAGE gel and HPLC analyses.


SDS-PAGE result
HPLC result



Bioactivity:

Determined by the dose-dependent stimulation of the proliferation of Balb/c 3T3 cells.The expected ED50 for this effect is 1.0-3.0 ng/ml.


The ED50 was determined by the dose-dependent stimulation of the proliferation of murine D10S cells is
0.05 ng/ml, corresponding to a specific activity of 2 x 107
units/mg.